Optimi Health Provides Corporate Update
Optimi Health Corp. (OPTHF) has announced two key financial updates. First, the company plans to close a second and final tranche of a non-brokered private placement, issuing 131,666 units at CAD$0.30 per unit for gross proceeds of CAD$395,000. Each unit includes one common share and half of a transferable purchase warrant exercisable at CAD$0.40 for two years.
The warrants include an accelerated expiry provision if the company's stock price exceeds CAD$0.50 for 20 consecutive trading days. The offering involves insider participation and will be used for general working capital. Additionally, Optimi is completing a debt settlement with two creditors, converting CAD$98,126.25 of marketing and investor relations services debt into common shares.
Both transactions are expected to close around January 24, 2025, with securities subject to a standard 4-month hold period.
Optimi Health Corp. (OPTHF) ha annunciato due aggiornamenti finanziari importanti. Innanzitutto, l'azienda prevede di chiudere una seconda e ultima tranche di un collocamento privato non intermediarato, emettendo 131.666 unità a CAD$0,30 per unità, per un incasso lordo di CAD$395.000. Ogni unità include un'azione comune e la metà di un warrant d'acquisto trasferibile esercitabile a CAD$0,40 per due anni.
I warrant prevedono una clausola di scadenza accelerata se il prezzo delle azioni dell'azienda supera CAD$0,50 per 20 giorni di trading consecutivi. L'offerta prevede la partecipazione di insider e sarà utilizzata per il capitale di lavoro generale. Inoltre, Optimi sta concludendo un accordo di estinzione del debito con due creditori, convertendo CAD$98.126,25 di debito per servizi di marketing e relazioni con gli investitori in azioni comuni.
Entrambe le transazioni dovrebbero chiudersi intorno al 24 gennaio 2025, con i titoli soggetti a un periodo di blocco standard di 4 mesi.
Optimi Health Corp. (OPTHF) ha anunciado dos actualizaciones financieras clave. En primer lugar, la empresa planea cerrar la segunda y última tranche de una colocación privada no intermedia, emitiendo 131,666 unidades a CAD$0.30 por unidad, para un ingreso bruto de CAD$395,000. Cada unidad incluye una acción común y la mitad de un warrant de compra transferible ejercitable a CAD$0.40 durante dos años.
Los warrants incluyen una disposición de vencimiento acelerado si el precio de las acciones de la empresa supera CAD$0.50 durante 20 días de cotización consecutivos. La oferta implica la participación de insiders y se utilizará para capital de trabajo general. Además, Optimi está completando un acuerdo de liquidación de deuda con dos acreedores, convirtiendo CAD$98,126.25 de deuda por servicios de marketing y relaciones con inversionistas en acciones comunes.
Se espera que ambas transacciones se cierren alrededor del 24 de enero de 2025, con los valores sujetos a un período estándar de restricción de 4 meses.
Optimi Health Corp. (OPTHF)는 두 가지 주요 재무 업데이트를 발표했습니다. 첫째, 회사는 비중개 사모 배치의 두 번째이자 최종 분할을 마감할 계획이며, CAD$0.30의 단가로 131,666개의 유닛을 발행하여 총 CAD$395,000의 수익을 올릴 예정입니다. 각 유닛은 하나의 일반주식과 CAD$0.40로 2년 동안 행사할 수 있는 구매 워런트의 절반을 포함합니다.
워런트에는 회사 주가가 연속적으로 20일 동안 CAD$0.50를 초과할 경우 가속 만료 조항이 포함되어 있습니다. 이 제안은 내부자 참여가 포함되며 일반 운영 자금으로 사용될 예정입니다. 또한, Optimi는 두 명의 채권자와 함께 부채 해결을 완결하고 있으며, 마케팅 및 투자자 관계 서비스에 대한 CAD$98,126.25의 부채를 일반 주식으로 전환하고 있습니다.
두 거래 모두 2025년 1월 24일 경에 마감될 것으로 예상되며, 증권은 표준 4개월 유예 기간의 적용을 받습니다.
Optimi Health Corp. (OPTHF) a annoncé deux mises à jour financières clés. Tout d'abord, la société prévoit de clôturer une seconde et dernière tranche d'un placement privé non intermédié, émettant 131 666 unités au prix de CAD$0,30 par unité pour un produit brut de CAD$395 000. Chaque unité comprend une action ordinaire et la moitié d'un bon de souscription transférable exerçable à CAD$0,40 pendant deux ans.
Les bons de souscription comprennent une clause d'expiration accélérée si le prix de l'action de l'entreprise dépasse CAD$0,50 pendant 20 jours de bourse consécutifs. L'offre implique la participation d'insiders et sera utilisée pour le fonds de roulement général. De plus, Optimi complète un règlement de dettes avec deux créanciers, convertissant CAD$98 126,25 de dettes pour des services de marketing et de relations investisseurs en actions ordinaires.
Les deux transactions devraient se clôturer autour du 24 janvier 2025, les titres étant soumis à une période de blocage standard de 4 mois.
Optimi Health Corp. (OPTHF) hat zwei wichtige finanzielle Updates angekündigt. Erstens plant das Unternehmen, eine zweite und letzte Tranche einer nicht vermittelten Privatplatzierung abzuschließen und 131.666 Einheiten zu einem Preis von CAD$0,30 pro Einheit auszugeben, was einem Bruttoertrag von CAD$395.000 entspricht. Jede Einheit umfasst eine Stammaktie und die Hälfte eines übertragbaren Kaufwarrants, der für zwei Jahre zu CAD$0,40 ausgeübt werden kann.
Die Warrants enthalten eine beschleunigte Ablaufregelung, wenn der Aktienkurs des Unternehmens 20 aufeinanderfolgende Handelstage CAD$0,50 übersteigt. Das Angebot beinhaltet die Teilnahme von Insidern und wird zur allgemeinen Betriebskapitalfinanzierung verwendet. Darüber hinaus schließt Optimi gerade eine Schuldenregulierung mit zwei Gläubigern ab, durch die CAD$98.126,25 Schulden für Marketing- und Investor Relations-Dienstleistungen in Stammaktien umgewandelt werden.
Es wird erwartet, dass beide Transaktionen um den 24. Januar 2025 abgeschlossen werden, wobei die Wertpapiere einer standardmäßigen Haltefrist von 4 Monaten unterliegen.
- Raising CAD$395,000 in additional capital through private placement
- Reduction of CAD$98,126.25 in debt through equity conversion
- Insider participation in private placement indicating management confidence
- Dilution of existing shareholders through new share issuance
- Need for additional working capital suggests cash flow concerns
- Settling debt through share issuance indicates potential cash constraints
Non-Brokered Private Placement and Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to close a second and final tranche of a non-brokered private placement by issuing 131,666 units (each a "Unit") at CAD
Debt Settlement
The Company is completing a debt settlement with 2 creditors which will result in an aggregate of CAD
About Optimi Health Corp.
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant manufacturer and supplier of natural psilocybin and MDMA. Dedicated to producing high-quality psychedelic products, the Company aims to support the global advancement of mental health therapies through rigorous compliance, innovation, and collaboration.
On Behalf of the Board
JJ Wilson, Chair of the Board
For more information, please contact:
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including statements pertaining to the completion of the Offering and the Debt Settlement. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's long form prospectus dated February 12, 2021, a copy of which is available on SEDAR+ at www.sedarplus.com. Except as expressly required by applicable law, Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237609
FAQ
What is the size and price of Optimi Health's (OPTHF) latest private placement?
What are the terms of OPTHF's warrant acceleration clause?
How much debt is Optimi Health (OPTHF) converting to equity in January 2025?
When will OPTHF's private placement and debt settlement close?
What is the exercise price and term of OPTHF's new warrants?
